Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. - Wikidata - awgldk - TriplyDB

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.

http://www.wikidata.org/entity/Q33386057

about

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes The evolving treatment paradigm in myelofibrosis A phase-2 trial of low-dose pomalidomide in myelofibrosis.Immunomodulatory agents in myelofibrosis.Ruxolitinib: a new treatment option for myelofibrosis.Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis.Efficacy of ruxolitinib for myelofibrosis.Long-term results of prednisone treatment for the anemia of myelofibrosis.Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results.Alleviating anemia and thrombocytopenia in myelofibrosis patients.Managing patients with myelofibrosis and low platelet counts.Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.Modest activity of pomalidomide in patients with myelofibrosis and significant anemia Chronic myeloproliferative neoplasms: a collaborative approach.Profile of pomalidomide and its potential in the treatment of myelofibrosis.Chromosome 5q deletion is extremely rare in patients with myelofibrosis The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3 Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence Clinical trials with anti-angiogenic agents in hematological malignancies.Experimental therapeutics for patients with myeloproliferative neoplasias.Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.Therapeutic approaches in myelofibrosis.New JAK2 inhibitors for myeloproliferative neoplasms.Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.Management of myeloproliferative neoplasms: from academic guidelines to clinical practice.BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.Emerging targeted therapies in myelofibrosis.

P2860

Q24186554-D9D99340-4C75-44F0-B88E-3BE59B2BFD51 Q24201893-01B98CDF-D364-4B23-AE01-A913A5CD6A0B Q24607513-6DC46195-1C9C-49E4-8245-614514632F0B Q26752940-D717B3D9-9430-43F9-8B9A-CFB390AAA2DC Q27021968-835E7D78-84FD-4A89-9D45-0B1E866B0288 Q33392689-B08F4465-5E91-4CA1-AF46-726A20BAB34E Q33401615-8E09F950-E1E6-4B66-80BA-1F966C1175FF Q33405241-15B8074E-49E2-4F55-AE5E-4B2FA00B0632 Q33406694-07A6BD8A-0BE8-40C1-825C-01306BD75D9D Q33415489-9B0C089B-8CE0-4FD1-B565-28FA97B3A498 Q33422565-1918AC5D-5BA5-44F8-9DEF-7F4372E0EA18 Q33423956-E93B84D4-37CC-4E69-ABEC-46CB99A6C0D5 Q33430113-FA255756-6E10-47DA-BF2B-B6F2D99B8FD5 Q33432406-D66FFC68-63CA-4000-82C3-2853D2019626 Q33779309-3995DE68-FA6C-4E3B-B3A7-AD9F285F7C40 Q33874179-B14DBF29-83BF-461F-9B83-B59D4E3E71A6 Q34146512-34C6CB4E-A032-4705-A87E-27CDCA71FF2A Q34150008-263488DE-4BCC-4CCE-9684-C18416A36801 Q34165935-1BE9B422-EAB3-4759-84B4-B5D3025D6649 Q34253548-75B5CD13-EF0D-410B-8941-BE53CDCAABA8 Q34293419-3A02B9A7-5C79-4B1D-86F4-65D3018AAC81 Q34512203-97EC324C-96B3-4CBE-BF59-22D67DEF3DAD Q34549335-85FA7B53-2562-4C77-B1B5-8D1442051039 Q35427915-ED320FCE-2809-49C5-9F0A-E6EF68A5A462 Q35535523-06FC7BCC-EC85-4250-8362-3B032680975F Q35849342-44B679B4-C0E3-4BC3-8258-5D3016D6CED5 Q37019322-D7C9D862-0D73-44DB-8023-2014DD6C4BDB Q37034988-4959134A-6B2A-4281-B98C-6F5188A0B780 Q37163590-8B1A2FC9-AC21-41CA-9BC6-66C0A881A6A1 Q37216367-6A8B5858-87E4-4107-B43F-954EF4E8F784 Q37740928-0D1C7875-DFE9-46B3-98E9-6209D6029F94 Q37766940-797D4D49-8351-48A9-AD82-BB3639DCF13C Q37797983-914A26EB-4178-44DB-A171-4D22EF94891C Q37833893-1D03649F-376D-46D2-A73F-552CB2A9527F Q37860336-23461DAF-0CB7-41F3-B915-4354E4F27088 Q37869152-2DB39CAB-BDBC-49F7-B504-33F1BC9B35B8 Q37956603-7A529F54-AE67-4526-87C4-388F7960E249 Q37978815-ABE9AFE8-E7AC-44F9-B3F7-5EFD91437AFC Q38014534-FC84C1A6-D0CE-4ED8-899F-60406F6F43E8 Q38025160-6C1919AD-57A2-42BB-8B33-6A1181098EC9

P2860

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.

http://www.wikidata.org/entity/Q33386057

description

2009 nî lūn-bûn

@nan

2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Lenalidomide plus prednisone r ...... n patients with myelofibrosis.

@ast

Lenalidomide plus prednisone r ...... n patients with myelofibrosis.

@en

type

label

Lenalidomide plus prednisone r ...... n patients with myelofibrosis.

@ast

Lenalidomide plus prednisone r ...... n patients with myelofibrosis.

@en

prefLabel

Lenalidomide plus prednisone r ...... n patients with myelofibrosis.

@ast

Lenalidomide plus prednisone r ...... n patients with myelofibrosis.

@en

P1433

Q33386057-6BB291D1-F81C-461B-966A-82D940C02C3F

P1476

Q33386057-51C54EA8-D9C2-41CD-AEDC-FA89267880F1

P2093

Q33386057-840160AC-E29B-473B-BC88-7D2D0AA0FFB9

Q33386057-99793EA4-3FC6-4E65-81E7-BB26B86B473C

Q33386057-A0BD7783-59FB-4FF2-A12E-65861A0E807C

Q33386057-AEE0D861-1C95-4D7E-AAFC-A67770D25519

P2860

Q33386057-07ED0B56-3B6F-4AD8-8D19-36F874FB13B8

Q33386057-21F2351B-71F7-4F35-83A5-FBD88EBA1CBE

Q33386057-2365B1DD-2F13-43E3-9475-861887C90EAC

Q33386057-26D5BB20-AEE3-4192-A839-EBFBB6712B70

Q33386057-2BF35E05-16E9-4955-8F77-EC5A9D909337

Q33386057-30A51F4B-C107-4736-A91E-4339F8570DA7

Q33386057-3649CC2F-7B34-4ED8-9D3C-B3020E624893

Q33386057-38711CCA-B520-4A4E-83AE-15E50091A586

Q33386057-4F1DB0F1-7472-436A-B6BC-5DB2B814B03E

Q33386057-56B14B16-EAF1-420C-9384-FE71981856CF

P304

Q33386057-CED4EDC1-238F-4B0D-8FAE-65D931E4C817

P31

Q33386057-BA6687F5-5CD8-445C-BB34-79F6D9B5F40E

P356

Q33386057-E2326EA4-DA1B-4D7B-A5A4-CCD7ED05FBC3

P407

Q33386057-967D620C-A719-4A08-8B69-F1960552BD4D

P433

Q33386057-D951714F-8AEC-411B-8E21-45C0368F4E8E

P478

Q33386057-3BE7664F-2E7B-47AB-8723-BED2B078A339

P50

Q33386057-3A5C7338-3326-4BD6-8A3A-AC89A2BB8454

Q33386057-3E664BEE-5B5B-4FB4-95B4-4F20C87D25EA

Q33386057-56D09B5B-C09E-4CBD-9B28-217EB75EBC9D

Q33386057-8457F135-A5FD-4A7A-929D-78AD3C2E5A60

Q33386057-9E33C2CE-3550-4618-A0E9-D403420011B0

Q33386057-EC2CF744-8E5B-48A1-8BF0-A020CB65D9C8

P577

Q33386057-3DBAEAD0-A5AB-4926-83A1-E7B90918ACB1

P698

Q33386057-41935A02-E776-4285-8450-E00122ED7BE9

P932

Q33386057-8B769F60-C255-435F-A0FC-69CFCE811D83

P356

JCO.2009.22.6548

P1433

Journal of Clinical Oncology

P1476

Lenalidomide plus prednisone r ...... n patients with myelofibrosis.

@en

P2093

Alfonso Quintás-Cardama

http://www.w3.org/2001/XMLSchema#string

Carlos Bueso-Ramos

http://www.w3.org/2001/XMLSchema#string

Deborah Thomas

http://www.w3.org/2001/XMLSchema#string

Taghi Manshouri

http://www.w3.org/2001/XMLSchema#string

P2860

Risk of thrombosis with lenalidomide and its prevention with aspirin

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

A gain-of-function mutation of JAK2 in myeloproliferative disorders

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

European consensus on grading bone marrow fibrosis and assessment of cellularity.

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.

Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.

Efficacy of lenalidomide in myelodysplastic syndromes.

Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

P304

4760-4766

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.22.6548

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Jorge Eduardo Cortes

Hagop Kantarjian

Alessandra Ferrajoli

Srdan Verstovsek

Guillermo Garcia-Manero

P577

2009-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19720904

http://www.w3.org/2001/XMLSchema#string

P932

4879697

http://www.w3.org/2001/XMLSchema#string